<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">JOACP</journal-id><journal-id journal-id-type="publisher-id">J Anaesthesiol Clin Pharmacol</journal-id><journal-title-group><journal-title>Journal of Anaesthesiology, Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0970-9185</issn><issn pub-type="epub">2231-2730</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9438825</article-id><article-id pub-id-type="publisher-id">JOACP-38-148</article-id><article-id pub-id-type="doi">10.4103/joacp.joacp_305_21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to Editor</subject></subj-group></article-categories><title-group><article-title>Remdesivir induced bradycardia and QT prolongation: A rare side effect of a ubiquitous drug of the COVID -19 era</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singla</surname><given-names>Karan</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Sanjeev</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Behl</surname><given-names>Ajay</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Puri</surname><given-names>Goverdhan D.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India</aff><aff id="aff2"><label>1</label>Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India</aff><author-notes><corresp id="cor1">
<bold>Address for correspondence:</bold> Dr. Karan Singla, Department of Anaesthesia and Intensive Care, 4<sup>th</sup> Floor, Nehru Hospital, A Block, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh - 160 012, India. E-mail: <email xlink:href="karansingla16@gmail.com">karansingla16@gmail.com</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2022</year></pub-date><volume>38</volume><issue>Suppl 1</issue><fpage>S148</fpage><lpage>S149</lpage><history><date date-type="received"><day>13</day><month>6</month><year>2021</year></date><date date-type="rev-recd"><day>22</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2021</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2022 Journal of Anaesthesiology Clinical Pharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>Remdesivir, an antiviral, approved for the treatment of COVID-19, is an adenosine nucleotide analog. Despite its widespread use, its cardiovascular side effects have not been extensively reported.</p><p>An 80-year old, diabetic and hypertensive patient, with a history of Coronary Artery Bypass Grafting (CABG) ten years back, was admitted to COVID ICU with complaints of fever, shortness of breath and cough of 3 days. His regular medications included aspirin 75 mg, Ramipril 5 mg, atorvastatin 10 mg, sitagliptin 50 mg and metformin 500 mg. He had no history of steroid or any antibiotic intake prior to hospital admission.</p><p>His heart rate was 70-75 beats/min, BP 140/70 mm Hg and oxygen saturation (SpO2) 94% on nasal oxygen at 4 lt/min. His ECG showed QT interval of 400 msec and right bundle branch block [<xref rid="joacp_305_21-f001" ref-type="fig">Figure 1</xref>]. He was prescribed intravenous dexamethasone 6 mg and Remdesivir 200 mg on day 1 followed by 100 mg for next 4 days. After third dose of Remdesivir patient had episodes of bradycardia (heart rate = 48/min) with prolongation of QT interval, [QTc 486 msec, <xref rid="joacp_305_21-f002" ref-type="fig">Figure 2</xref>], though the patient was asymptomatic. His serum electrolytes (sodium -134 mmol/L, Potassium 4.4 mmol/L, Calcium 8.8 mg/dL), Pro-BNP (Brain natriuretic peptide), Troponin T, CK-MB (creatinine kinase-MB), and 2-D echocardiography, were normal. After ruling out drug error, Remdesivir was considered the probable cause for the QTc prolongation, and hence was discontinued. Other differential diagnosis was viral myocarditis, however normal cardiac enzymes and echo ruled it out. Underlying cardiac condition could also have contributed to the observed phenomenon. Two days after stopping the drug, QTc interval returned to baseline [QTc - 420 msec, <xref rid="joacp_305_21-f003" ref-type="fig">Figure 3</xref>].</p><fig position="float" id="joacp_305_21-f001"><label>Figure 1</label><caption><p>Electrocardiogram at admission, before remdesivir administration</p></caption><graphic xlink:href="JOACP-38-148-g001" position="float"/></fig><fig position="float" id="joacp_305_21-f002"><label>Figure 2</label><caption><p>Electrocardiogram 2 days after starting remdesivir</p></caption><graphic xlink:href="JOACP-38-148-g002" position="float"/></fig><fig position="float" id="joacp_305_21-f003"><label>Figure 3</label><caption><p>Electrocardiogram 2 days after withdrawal of remdesivir</p></caption><graphic xlink:href="JOACP-38-148-g003" position="float"/></fig><p>Remdesivir&#x02019;s active form resembles adenosine triphosphate, inhibiting viral RNA-dependent RNA polymerases, enzymes required for the multiplication of Corona virus.[<xref rid="R1" ref-type="bibr">1</xref>] Its efficacy in the COVID-19 pandemic was shown by the ACTT-1 (Adaptive COVID-19 Treatment Trial) trial where patients treated with remdesivir had a shorter time to recovery than placebo. The ACTT-1 investigators demonstrated a 1.1% incidence of cardiac arrest in the patient group who received remdesivir, compared with 1.0% in the control group.[<xref rid="R2" ref-type="bibr">2</xref>]</p><p>Bradycardia with remdesivir has been reported, where the authors opined that the safety of remdesivir was dependent on the affinity of its active form for viral RNA polymerase compared to human mitochondrial RNA polymerase (h-mtRNAP).[<xref rid="R3" ref-type="bibr">3</xref>] Remdesivir&#x02019;s affinity for viral polymerases is &#x0003e;500 times than that of h-mtRNAP.[<xref rid="R4" ref-type="bibr">4</xref>] Although this affinity for viral RNA polymerase is considerable, possibility of cross-reaction with h-mtRNAP and subsequent mitochondrial dysfunction causing cardiotoxicity is still tenable.</p><p>Further, endogenous nucleoside, Adenosine has intrinsic electrophysiological effects on the myocardium, being used in the treatment of supraventricular tachycardias.[<xref rid="R5" ref-type="bibr">5</xref>] Since remdesivir is also a nucleoside analog that resembles adenosine triphosphate, its effects on the AV node warrants further investigation.</p><sec disp-level="2"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" disp-level="2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Sheahan</surname><given-names>TP</given-names></name>
<name><surname>Sims</surname><given-names>AC</given-names></name>
<name><surname>Graham</surname><given-names>RL</given-names></name>
<name><surname>Menachery</surname><given-names>DV</given-names></name>
<name><surname>Gralinski</surname><given-names>LE</given-names></name>
<name><surname>Case</surname><given-names>JB</given-names></name>
<etal/>
</person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci Transl Med</source><year>2017</year><volume>9</volume><fpage>eaal3653</fpage><comment>doi: 10.1126/scitranslmed.aal3653</comment><pub-id pub-id-type="pmid">28659436</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Beigel</surname><given-names>JH</given-names></name>
<name><surname>Tomashek</surname><given-names>KM</given-names></name>
<name><surname>Dodd</surname><given-names>LE</given-names></name>
<name><surname>Mehta</surname><given-names>AK</given-names></name>
<name><surname>Zingman</surname><given-names>BS</given-names></name>
<name><surname>Kalil</surname><given-names>AC</given-names></name>
<etal/>
</person-group><article-title>Remdesivir for the treatment of Covid-19 - Final Report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>1813</fpage><lpage>26</lpage><comment>doi: 10.1056/NEJMoa2007764</comment><pub-id pub-id-type="pmid">32445440</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Gubitosa</surname><given-names>JC</given-names></name>
<name><surname>Kakar</surname><given-names>P</given-names></name>
<name><surname>Gerula</surname><given-names>C</given-names></name>
<name><surname>Nossa</surname><given-names>H</given-names></name>
<name><surname>Finkel</surname><given-names>D</given-names></name>
<name><surname>Wong</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Marked sinus bradycardia associated with remdesivir in COVID-19: A case and literature review</article-title><source>JACC Case Rep</source><year>2020</year><volume>2</volume><fpage>2260</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">33163977</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Tchesnokov</surname><given-names>EP</given-names></name>
<name><surname>Feng</surname><given-names>JY</given-names></name>
<name><surname>Porter</surname><given-names>DP</given-names></name>
<name><surname>G&#x000f6;tte</surname><given-names>M</given-names></name>
</person-group><article-title>Mechanism of inhibition of Ebola virus RNA dependent RNA polymerase by remdesivir</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>326</fpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="editor">
<name><surname>Zipes</surname><given-names>DP</given-names></name>
<name><surname>Libby</surname><given-names>P</given-names></name>
<name><surname>Bonow</surname><given-names>RO</given-names></name>
<name><surname>Mann</surname><given-names>DL</given-names></name>
<name><surname>Tomaselli</surname><given-names>GF</given-names></name>
<name><surname>Braunwald</surname><given-names>E</given-names></name>
</person-group><article-title>Braunwald&#x02019;s Heart Disease: A Textbook of Cardiovascular Medicine</article-title><year>2018</year><edition>11th ed</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Elsevier/Saunders</publisher-name></element-citation></ref></ref-list></back></article>
